Aligos Therapeutics Inc. (ALGS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALGS Stock Price Chart Interactive Chart >
ALGS Price/Volume Stats
| Current price | $1.13 | 52-week high | $2.46 |
| Prev. close | $1.13 | 52-week low | $0.84 |
| Day low | $1.09 | Volume | 34,500 |
| Day high | $1.16 | Avg. volume | 401,263 |
| 50-day MA | $1.61 | Dividend yield | N/A |
| 200-day MA | $1.29 | Market Cap | 48.52M |
Aligos Therapeutics Inc. (ALGS) Company Bio
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Latest ALGS News From Around the Web
Below are the latest news stories about ALIGOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ALGS as an investment opportunity.
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue EstimatesAligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial ResultsSOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022. "Last year was very productive for our team,” said Lawrence Blatt, PhD, MBA, Chairman & CEO of Aligos. “We made great progress advancing our NASH |
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nonalcoholic steatohepatitis (NASH) and viral diseases, today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets. About AligosAligos Therapeutics, I |
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverSOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Conven |
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the LiverSOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convent |
ALGS Price Returns
| 1-mo | -31.10% |
| 3-mo | 24.23% |
| 6-mo | 13.00% |
| 1-year | -50.44% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 18.59% |
| 2022 | -91.97% |
| 2021 | -57.07% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...